
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is a biopharmaceutical company focused on developing, manufacturing, and commercializing products to treat pulmonary hypertension (PH) and related conditions using its proprietary PRINT technology. This technology allows for precise production of uniform drug particles, making Liquidia's products effective and appealing to patients. The company has seen impressive sales growth for its lead product, Yutrepia, and has a strong pipeline, with potential for expanded indications and new product launches. While there may be some competition in the market, Liquidia's products and technology position it for continued success and potential future growth.
Bears say
Liquidia is facing significant legal and competitive risks in the near future with ongoing patent disputes and potential delays in launching their lead candidate, Yutrepia, for the treatment of pulmonary hypertension. With potential disruptions in sales and no definite timeline for resolution, the company may struggle to achieve peak commercial revenue. Additionally, competition from other companies in the market may also impede their success. Despite a positive outlook from KOL sentiment and increased market penetration, these factors significantly increase the risk surrounding Liquidia's stock.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares